Days like these obviously make investors like Viking Global happy, and Soliris is still the only drug in the PNH and aHUS space. A lack of competition is always a good sign, but it’s important to note that Alexion has a quartet of other rare-disease drugs in development, with a hypophosphatasia-focused treatment taking the reins as front-runner to pair with Soliris at the moment.
The final stock in the fund’s top five is LyondellBasell Industries NV (NYSE:LYB), a chemical company. Viking’s management team increased their investment by 74% last quarter, taking the total shares owned to more than 13 million, valued at $830 million. Shares of LyondellBasell Industries NV (NYSE:LYB) are up double-digits year-to-date, and the crux of this stock’s bullish thesis lies in its ability to capitalize on the ethylene boom, which is made from a shale derivative. This analyst seems to think that a MLP spinoff might be in the cards—and should at least be considered—which may be something Halvorsen is watching.
Halverson has made some important changes to Viking Global’s equity portfolio, with the addition of The Boeing Company (NYSE:BA), and continued support of LyondellBasell, Alexion Pharmaceuticals, Intuitive Surgical and Time Warner Inc (NYSE:TWX). Each of these stocks has its own unique growth driver moving forward, and we’ll be monitoring them closely. Continue preparing for 13F-filing season here.